

**In the claims:**

1-16. (canceled).

17. (currently amended). A method for treating late infantile neuronal ceroid lipofuscinosis (LINCL) ~~LINCL~~ in an animal by increasing the level of CLN2 in cells of the animal, wherein the level of CLN2 is increased by administering a recombinant adeno-associated viral (AAV) vector to nervous system cells of the animal, wherein the recombinant AAV vector is administered intracranially and comprises a nucleic acid sequence encoding a CLN2 polypeptide comprising SEQ ID NO: 3 or a nucleic acid sequence encoding a CLN2 polypeptide comprising an amino acid sequence 90% homologous to SEQ ID NO: 3.

18. (currently amended). The method according to Claim 17, wherein the recombinant AAV vector comprises a nucleic acid sequence encoding a CLN2 polypeptide comprising SEQ ID NO: 3 ~~level of CLN2 is increased by administration of CLN2 to the animal.~~

19-30. (canceled).